Programs and Networks
Atopic Dermatitis and Vaccinia Network
Three contracts support research to reduce the incidence and severity of eczema vaccinatum (EV), a disseminated viral infection following smallpox immunization, occuring almost exclusively in subjects with atopic dermatitis. Clinical and animal studies of innate and adaptive immunity, skin barrier function, genetic markers and gene expression aim to identify the risk of EV from exposure to/challenge with vaccinia or surrogate viruses.
http://www.atopicderm.org/advn/index.aspx
Clinical Trials in Organ Transplantation
https://www.ctotstudies.org/
Cooperative Centers for Translational Research on Human Immunology and Biodefense
The mission of these eight research centers is to further our knowledge of human immune responses against infectious pathogens and to understand the molecular mechanisms responsible for both short-term immunity and long-term immune memory. The overall goal of the program is to translate research on immunity to infection into clinical applications in humans to protect against bioterrorist threats.
Cooperative Clinical Trials in Pediatric Transplantation
https://www.cctptstudies.org/
Cooperative Study Group for Autoimmune Disease Prevention
Formation and History
The Cooperative Study Group for Autoimmune Disease Prevention (CSGADP) was established in 2001 as a collaborative network of investigators with a focus on prevention of autoimmune disease, defined as halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression, and an emphasis on type 1 diabetes.
Learn more.
Immune Epitope Database
http://www.immuneepitope.org
Immune Function and Biodefense in Children, Elderly and Immunocompromised Populations
A variety of human populations (children, the elderly, and persons who do not have normal immune responses) are studied under ten contracts in this program. The studies focus on defining the molecular basis for differential immune capabilities in combating infection or responding to vaccination at different stages of life or different underlying health problems.
Immune Tolerance Network
http://www.immunetolerance.org/
Innate Immune Receptors and Adjuvant Discovery
DAIT supports five contracts to discover and characterize innate immune receptors that are important for the development of new adjuvants (chemical compounds that enhance immune response); these adjuvants would exploit the natural capacity of the innate immune system to initiate and sustain appropriate T and B cell responses to novel vaccines against infectious agents.
Large Scale Antibody and T Cell Epitope Discovery
This program supports interactive multidisciplinary teams under fourteen contracts to identify novel antibody and T cell epitopes (parts of proteins that antibodies or T cells will recognize) associated with microorganisms that are potential agents of bioterrorism, their toxins, and re-emerging and emerging infectious diseases. This work contributes to the development of new candidates for vaccines and new reagents for characterizing those immune responses that correlate with the protection a vaccine confers.
Modeling Immunity for Biodefense
Four contracts support mathematical modeling and computational analyses of immunity to provide novel perspectives on immune responses to infection or vaccination. The modeling approach includes characterizing both innate and adaptive immune responses to pathogens or their vaccines through iterative studies that include predictions based on modeling and experimental testing of these models in the laboratory.
Population Genetics Analysis Program: Immunity to Vaccines/Infections
Six contracts supported under this program define the associations between gene sequence variations among individuals and susceptibility to infection or the quality of response to vaccination. Further studies look at correlations of outcomes with genetic variations by analyzing protein expression levels and protein function.
Solid Organ Transplantation in HIV: Multi-Site Study
https://web.emmes.com/study/htr/
back to top